The global infertility drugs market is expected to witness substantial growth, with the market size projected to increase from USD 3,589.97 million in 2022 to USD 6,453.7 million by 2032, reflecting a ...

New data add to the body of evidence favoring the aromatase inhibitor therapy plus ovarian suppression over tamoxifen for ...

Vaginal estrogen therapy appears to be safe after early breast cancer in patients with HR-negative tumors and those with ...

Stratification by concurrent endocrine partner showed that patients with ESR1 mutations had worse outcomes when a CDK4/6 inhibitor was paired with an aromatase inhibitor but not with fulvestrant.